A study has shown that Roche's diabetic macular oedema (DME ... read about two and a half more lines (12.3 letters) on an eye chart, a result that was consistent with the phase 3 studies that ...

Study from Case Western Reserve University and VA Northeast Ohio Healthcare System examines genetic risk profiles across ...

Oculis' main value driver appears to be OCS-01, which targets a respectable $4B DME TAM with its non-invasive eye drops. See ...

A new study has revealed that managing eye conditions through enhanced optometric services at local optometrists, rather than ...

Data from various retinal clinical trials suggest that there is a difference in efficacy in anti-VEGF therapies for patients with lower vision, according to a speaker here. During a presentation at ...

Age-related macular degeneration may cause a gradual reduction in your central vision over time, so you might not recognize AMD at first.

An injured cornea is often very painful. You may also have blurry vision, redness, tearing, and the feeling of something being in the affected eye. Macular degeneration begins when the center of the ...

EYE-103 is under clinical development by Eyebiotech and currently in Phase III for Diabetic Macular Edema. According to GlobalData, Phase III drugs for Diabetic Macular Edema have a 62% phase ...

The Amsler grid tests the condition of the center of the retina or "macula". It is a good test for screening for the development of "wet" macular degeneration in patients with "dry" macular ...

Approximately a quarter of Medicare Advantage prescription drug plan members with geographic atrophy also have wet AMD.